GAS2L1 Is a Potential Biomarker of Circulating Tumor Cells in Pancreatic Cancer

Zhu, Lei; Kan, Kejia; Grün, Johanna; Hissa, Bárbara; Yang, Cui; Győrffy, Balázs; Loges, Sonja; Reißfelder, Christoph; Schölch, Sebastian

doi:10.3390/cancers12123774

Cited by 12 publications

(7 citation statements)

References 65 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CLIC4 knockdown suppressed cell growth and apoptosis, and apoptosis induction by FxOH was reduced with CLIC4 knockdown. The expression levels of CLIC4 and GAS2L1 were found to be higher in circulating tumor cells (CTCs) from pancreatic cancer patients compared to peripheral blood mononuclear cells [93]. Besides, the overexpression of CLIC4 was associated with unfavorable outcomes in multiple cohorts of CN-AML patients [33].…”

Section: Pathway 3: Ctla4-cd2mentioning

confidence: 99%

Biomarker discovery with quantum neural networks: a case-study in CTLA4-activation pathways

Nguyen

2024

BMC Bioinformatics

View full text Add to dashboard Cite

Background Biomarker discovery is a challenging task due to the massive search space. Quantum computing and quantum Artificial Intelligence (quantum AI) can be used to address the computational problem of biomarker discovery from genetic data. Method We propose a Quantum Neural Networks architecture to discover genetic biomarkers for input activation pathways. The Maximum Relevance-Minimum Redundancy criteria score biomarker candidate sets. Our proposed model is economical since the neural solution can be delivered on constrained hardware. Results We demonstrate the proof of concept on four activation pathways associated with CTLA4, including (1) CTLA4-activation stand-alone, (2) CTLA4-CD8A-CD8B co-activation, (3) CTLA4-CD2 co-activation, and (4) CTLA4-CD2-CD48-CD53-CD58-CD84 co-activation. Conclusion The model indicates new genetic biomarkers associated with the mutational activation of CLTA4-associated pathways, including 20 genes: CLIC4, CPE, ETS2, FAM107A, GPR116, HYOU1, LCN2, MACF1, MT1G, NAPA, NDUFS5, PAK1, PFN1, PGAP3, PPM1G, PSMD8, RNF213, SLC25A3, UBA1, and WLS. We open source the implementation at: https://github.com/namnguyen0510/Biomarker-Discovery-with-Quantum-Neural-Networks.

show abstract

Section: Pathway 3: Ctla4-cd2mentioning

confidence: 99%

Biomarker discovery with quantum neural networks: a case-study in CTLA4-activation pathways

Nguyen

2024

BMC Bioinformatics

View full text Add to dashboard Cite

show abstract

“…Specific biomarker identification using single-cell approaches has mainly been performed in the context of oncology. [139][140][141][142] In the context of SOT, Lei et al 143 recently identified Cat-S and PAR-2 as potential therapeutic targets in acute renal allograft rejection. Via similar approaches, novel diagnostic biomarkers that predict the risk of allograft rejection or tolerance can be discovered.…”

Section: Biomarker Identification and Risk Stratificationmentioning

confidence: 99%

The Value of Single-cell Technologies in Solid Organ Transplantation Studies

et al. 2022

View full text Add to dashboard Cite

Single-cell technologies open up new opportunities to explore the behavior of cells at the individual level. For solid organ transplantation, single-cell technologies can provide in-depth insights into the underlying mechanisms of the immunological processes involved in alloimmune responses after transplantation by investigating the role of individual cells in tolerance and rejection. Here, we review the value of single-cell technologies, including cytometry by time-of-flight and single-cell RNA sequencing, in the context of solid organ transplantation research. Various applications of single-cell technologies are addressed, such as the characterization and identification of immune cell subsets involved in rejection or tolerance. In addition, we explore the opportunities for analyzing specific alloreactive T-or B-cell clones by linking phenotype data to T-or B-cell receptor data, and for distinguishing donor-from recipient-derived immune cells. Moreover, we discuss the use of single-cell technologies in biomarker identification and risk stratification, as well as the remaining challenges. Together, this review highlights that single-cell approaches contribute to a better understanding of underlying immunological mechanisms of rejection and tolerance, thereby potentially accelerating the development of new or improved therapies to avoid allograft rejection.

show abstract

“…The main therapies currently include surgery, chemo-/radiotherapy, immunotherapy and targeted drugs, such as inhibitors for vascular endothelial growth factor or EGFR [8][9][10][11][12]. Early detection is important for cancer diagnosis; however, as effective screening methods for PC are limited, most patients are diagnosed in the mid-late stage of the disease [13][14][15]. In addition, high metastatic potential and resistance to chemotherapy result in poor patient outcomes [16,17].…”

Section: Introductionmentioning

confidence: 99%

Human CPTP promotes growth and metastasis via sphingolipid metabolite ceramide and PI4KA/AKT signaling in pancreatic cancer cells

Zhang¹,

Ji²,

Zhang³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a devastating solid malignancy with a dismal prognosis. The treatment of metastatic PC is a current challenge for medical oncologists due to a lack of early detection, drug resistance, and relapse. Therefore, potential biomarkers and effective therapeutic targets for PC are urgently required. Ceramide-1-phosphate transfer protein (CPTP) is a member of the glycolipid transfer protein family, which is associated with autophagy and inflammation regulation. The roles and mechanisms of CPTP in PC have not been clarified. In this study, by RT-qPCR and immunohistochemistry analysis, we found that CPTP is highly expressed in PC and is associated with a poor prognosis in PC patients. By using cell counting kit-8, colony formation, transwell and matrigel assays in vitro , as well as xenograft model assays in vivo , we further proved that CPTP enhanced PC cells growth and metastasis. In PC cells, human CPTP promotes growth and metastasis via sphingolipid metabolite ceramide and PI4KA/AKT signaling. Sp (specific protein)-1 and Sp3 transcription factors also act as upstream positive regulators of CPTP expression in PC cells. Collectively, these findings suggested that CPTP may function as a pro-tumorigenic gene in PC cells and could be a promising therapeutic target in PC.

show abstract

GAS2L1 Is a Potential Biomarker of Circulating Tumor Cells in Pancreatic Cancer

Cited by 12 publications

References 65 publications

Biomarker discovery with quantum neural networks: a case-study in CTLA4-activation pathways

Biomarker discovery with quantum neural networks: a case-study in CTLA4-activation pathways

The Value of Single-cell Technologies in Solid Organ Transplantation Studies

Human CPTP promotes growth and metastasis via sphingolipid metabolite ceramide and PI4KA/AKT signaling in pancreatic cancer cells

Contact Info

Product

Resources

About